Targeted therapy for advanced gynecological cancers with KRAS G12D mutation
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new oral medication (RNK08954) that may target tumors with a specific genetic mutation (KRAS G12D). It's for people with advanced gynecological cancers like ovarian, endometrial, or cervical cancer that haven't responded to prior treatments. The goal is to see if the drug is safe and can help shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and are female.
- You have a type of gynecological cancer (like ovarian, endometrial, or cervical) that has not responded to at least one previous treatment.
- Your tumor has a specific genetic change called KRAS G12D mutation.
- You are generally able to take care of yourself (not bedridden) and have a life expectancy of at least 12 weeks.
- You have a measurable tumor on imaging (scans).
- You agree to use effective contraception during the trial and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, HRS-6093, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and effective for those who have not responded to or cannot tolerate other treatments.
This trial tests two pills together (GH21 and D-1553) for people whose cancer has a specific genetic marker called KRAS G12C. The goal is to see if this combination can shrink tumors or slow cancer growth, especially after other treatments have stopped working.
This trial tests an experimental drug called LT-010391 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The drug is designed to target this mutation, and the study aims to see if it can help when standard treatments are no longer working.
This trial tests a new oral drug called RNK08954 for people with advanced solid tumors that have a specific KRAS G12D genetic change. The drug targets this mutation to try to stop tumor growth. It is for patients who have already had other treatments and may not have many options left.
This early-stage trial tests a new drug called INV-8989 designed to target a specific genetic mutation (KRAS G12D) found in some advanced solid cancers. The study will evaluate whether the drug is safe and if it can help shrink tumors in patients who haven't responded to standard treatments.
This trial tests a new oral drug (GDC-7035) for people with advanced solid tumors that have a specific KRAS mutation (G12D). The drug may be given alone or with other treatments to see if it is safe and helps fight the cancer.
Hear when a new Advanced Gynecologic Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.